ClinicalTrials.gg
Drug

Mirdametinib clinical trials

Also written PD-0325901.

studies test it
27
open now
15
in phase 3
0
first study started
2004

How each study uses mirdametinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the mirdametinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
11 Feb 2025 · GOMEKLI · NDA 219379 (FDA, Drugs@FDA)
European Union
17 Jul 2025 · Ezmekly · EMEA/H/C/006460 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mirdametinib
17

Brand

Gomekli
1

Development codes

PD-0325901
13
PD-0325901-0000
1
PF-00192513-00
1
PD 901
1

Studies by the year they started

25 studies that test it; most in 2026 (6); 2 more planned to start later

Studies that test mirdametinib, by start year
YearStudies
20041
20051
20144
20192
20212
20231
20243
20255
20266

Who runs them

Industry 9 · Other 18

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (5) · Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · University of Alabama at Birmingham (2) · Pfizer (2) · BeiGene (1) · The Netherlands Cancer Institute (1) · Dana-Farber Cancer Institute (1)

Often tested with

Tested in the same studies.

Palbociclib (2) · Carbamazepine (1) · BGB-283 (1) · Vorinostat (1) · Alpelisib (1) · Sirolimus (1) · Brimarafenib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6

Studies that test mirdametinib.

Studies

Open first, then newest update. How each study uses mirdametinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 27

See all 27 studies that test mirdametinib →

Given beside what is tested · 1 — mirdametinib is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call mirdametinib · ClinicalTrials.gg INT004850

  • MeSH (NLM) C506614mirdametinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 86K0J5AK6MMIRDAMETINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q27088255mirdametinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C52195MirdametinibOne source FDA
  • DrugBank DB07101One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.